Cagrilintide Canada — 5 mg & 10 mg Lyophilized Vials, Janoshik-Tested

The references section of this page cites 2 primary papers published in 2025 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.

Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Cagrilintide, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.

Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.

Verification for Cagrilintide is per lot, not per product. Across the strengths currently stocked: 10mg lot CAGL-CA-26G-10 returned 99.605% purity, 11.66 mg measured, 116.6% of the labelled 10 mg; 5mg lot CAG-CA-26A-01 returned 99.446% purity, 5.62 mg measured, 112.4% of the labelled 5 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.

Purity is half the number. It states what fraction of the material in the vial is Cagrilintide; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Cagrilintide, across the strengths stocked they run from 112.4% to 116.6% of label. Both numbers are published for every lot, whichever way they fall.

Each strength of Cagrilintide carries its own lot code and its own certificate — CAGL-CA-26G-10, CAG-CA-26A-01 are separate tests, not one result applied across the range. The code printed on the vial you receive is the one to match, and matching it is what ties the material in hand to a test that was actually run on it.

Researchers who buy Cagrilintide in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.

Verify a batch code →

Lyophilized storage

−20 °C long-term; stable at room temperature in transit

After reconstitution

2–8 °C

Light

Protect from UV and direct light

Freeze-thaw

Avoid repeated cycles

Vehicle

Bacteriostatic water in most published protocols

Format

Lyophilized powder

Cagrilintide is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 37 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.

Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.

Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.

Reconstitution calculator →

Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.